Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflimrufusp alfa - RemeGen/Santen Pharmaceutical

Next Previous
Drug Profile

Eflimrufusp alfa - RemeGen/Santen Pharmaceutical

Alternative Names: RC 28 E; RC28-E injection; STN-1014300; STN-1014301

Latest Information Update: 19 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RemeGen; Yantai Rongchang Biological Engineering
  • Developer RemeGen
  • Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic retinopathy
  • Preregistration Submission Withdrawal Diabetic macular oedema

Most Recent Events

  • 06 Aug 2026 Santen Pharmaceutical plans a registrational clinical trials for Diabetic macular oedema in China (Intravitreous)
  • 30 Jun 2026 Regulatory submission withdrawn for Diabetic macular oedema in China (Intravitreous) (Santen Pharmaceutical pipeline, July 2026)
  • 30 Apr 2026 RemeGen completes the phase III trial in Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top